Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The aim of this study was to test the antifungal susceptibility of 262 bloodstream yeast isolates (164 Candida albicans strain, 88 non-albicans Candida spp. and 10 non-Candida yeasts) recovered from 169 surgical, neonatal, critically ill intensive care unit patients (ICU), and cancer patients (mixed patient population) to amphotericin B (AmB), fluconazole (FLU), 5-flucytosine (5-FC), itraconazole (ITRA), ketoconazole (KETO), miconazole (MICO), and nystatin (NYS), in order to correlate in-vitro resistance to fluconazole with the outcome of fungemia. The agar disk diffusion test was used to assess the susceptibility of the 262 bloodstream yeasts isolates. In addition, 78 strains isolated from cancer patients were also tested with the E-test. There were no differences in the susceptibility of the various C. albicans strains tested, except in 40 isolates from surgery patients, which showed a somewhat lower susceptibility to KETO and MICO to (3.7-5.5% resistance). There were no C. albicans strains resistant to AmB, NYS, or FLU. There were slight differences in the susceptibility patterns of the 88 non-albicans Candida spp. (NAC) isolates. Resistance to AmB and NYS appeared in 1 strain of C. guillermondii (minimum inhibitory concentration; MIC to AmB; 4 microg/ml) and in 1 strain of C. parapsilosis (MIC to NYS, 8 microg/ml and MIC to AmB, 2 microg/ml). All other NACs were susceptible to both polyenes (AmB and NYS). Nine of the 11 strains of C. krusei were resistant to FLU (MIC >or= 64 microg/ml), the 2 exceptions showed, respectively, MICs for FLU of 6 and 32 microg/ml ("dose-dependent" susceptibility). However, only 2 of 29 C. glabrata strains were fully FLU-resistant (MIC >or= 64 microg/ml), 27 being susceptible with MIC values of 0.5-8 microg/ml. Apart from 9 C. krusei and 2 C. glabrata strains, 2 C. parapsilosis strains and 1 strain of C. tropicalis were also FLU-resistant. Among the 88 NACs, 17.04% were FLU-resistant and 3.7% were KETO- and ITRA-resistant. Resistance to 5-FC and AmB was minimal. We compared the outcomes of patients infected with FLU-resistant vs FLU-susceptible yeasts in 161 evaluable patients treated with FLU. Attributable mortality was significantly higher (19.0% vs 8.6%; P < 0.01) in patients infected with the FLU-resistant yeasts.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Comparing fluconazole-susceptible with resistant strains in 161 patients, Kovacicova et al. [19] found a significantly higher attributable mortality in patients infected with a fluconazole-resistant strain.”
From Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis (2009) · cites this paper as [19]
Citations
Cites
Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514731 · Cited by 601
Self-citationNguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363
Rex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W., & Webb, C. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.40 · Cited by 301
Amphotericin B-resistant yeast infection in severely immunocompromised patients
Powderly, W. G., Kobayashi, G. S., Herzig, G. P., & Medoff, G. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90059-9 · Cited by 232
Nguyen, M. H., Clancy, C. J., Yu, V. L., Yu, Y. C., Morris, A. J., Snydman, D. R., Sutton, D. A., & Rinaldi, M. G. (1998) · The Journal of Infectious Diseases · doi:10.1086/514193 · Cited by 219
Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals
Voss, A., Kluytmans, J. A. J. W., Koeleman, J. G. M., Spanjaard, L., Vandenbroucke-Grauls, C. M. J. E., Verbrugh, H. A., Vos, M. C., Weersink, A. Y. L., Hoogkamp-Korstanje, J. A. A., & Meis, J. F. G. M. (1996) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01690507 · Cited by 128
Pfaller, M. A., Messer, S. A., Karlsson, Å., & Bolmström, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.9.2586-2589.1998 · Cited by 99
Troillet, N., Durussel, C., Billé, J., Glauser, M. P., & Chave, J. P. (1993) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01992164 · Cited by 96
Tumbarello, M., Caldarola, G., Tacconelli, E., Morace, G., Posteraro, B., Cauda, R., & Ortona, L. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.4.691 · Cited by 57
In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp.
Barchiesi, F. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.2.295 · Cited by 53
Evaluation of the susceptibility of pathogenicCandida species to fluconazole
Billé, J., Glauser, M. P., & Fluconazole Global Susceptibility Study Group (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01700561 · Cited by 35
Research works printed but not linked: 6
- Clancy, 1998, Correlation of fluconazole MIC and response to therapy for patients with candidemia due to C. albicans and non-C. albicans spp.: results of a multicenter prospective study of candidemia, Abstracts of the IDSA 36th annual meeting, Denver, abstract No., 98
- Pappas, 1998, Candidaemia in the United States, Clin Infect Dis 27, 4, 320
- Nguyen, 1995, Therapeutic approach in patients with candidaemia, Arch Intern Med 1995;, 155, 2429
- Viscoli, 1999, Candidemia in cancer patients. Results of a prospective, multicenter surveillance study in Europe, Clin Infect Dis, 27
- Durussel, 1998, Biomic reading of fluconazole agar disk diffusion susceptibility testing of Candida spp. clinical isolates compared to NCCLS microbroth dilution, Abstracts of the 40th ICAAC, 21-24 September, 1998, San Diego, abstract no., 3120
- Pfaller, 1999, Etiology and resistance to antifugals in Candida isolates from bloodstream infections, Diagn Microbiol Infect Dis, 27, 331
Cited by
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
“Finally, these breakpoints were developed on the basis of data from 2 groups of infected adult patients: patients with oropharyngeal and esophageal candidiasis (for fluconazole and itraconazole) and patients with invasive candidiasis (mostly nonneutropenic patients with candidemia; for fluconazole only) [30] and are s…”
Backgroundvan Asbeck, E. C., Clemons, K. V., & Stevens, D. A. (2009) · Critical Reviews in Microbiology · doi:10.3109/10408410903213393 · Cited by 210
“Similarly, Sarvikivi et al. (2005) observed fluconazole resistance in only one C. parapsilosis isolate during a 10-year period of fluconazole prophylaxis and Kovacicova et al. (2000) reported resistance in only two strains of C. parapsilosis, over a period of 3 years.”
BackgroundClancy, C. J., Yu, V. L., Morris, A. J., Snydman, D. R., & Nguyen, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3171-3177.2005 · Cited by 176
“3% (n 21) were infected with resistant isolates (11).”
BackgroundGuery, B. P., Arendrup, M. C., Auzinger, G., Azoulay, É., Borges Sá, M., Johnson, E. M., Müller, E., Putensen, C., Rotstein, C., Sganga, G., et al. (2009) · Intensive Care Medicine · doi:10.1007/s00134-008-1338-7 · Cited by 173
“[19] found a significantly higher attributable mortality in patients infected with a fluconazole-resistant strain.”
BackgroundFluconazole prophylaxis in critically ill surgical patients: A meta-analysis*
Shorr, A. F., Chung, K., Jackson, W. L., Waterman, P. E., & Kollef, M. H. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000178352.14703.49 · Cited by 166
“Likewise, in critically ill patients, infection with fluconazoleresistant Candida, independent of the particular species, doubles the risk for death (35).”
Background
Metadata
- Authors
- Kovacicova, G., Krupova, Y., Lovaszova, M., Obertik, T., Krcmery, V., Roidova, A., Trupl, J., Liskova, A., Hanzen, J., Milosovic, P., Lamosova, M., Szovenyiova, Z., Purgelova, A., Macekova, L., & Bille, J.
- Affiliations
- University of Trnava (SK)
- Corresponding author
- Krcmery, Vladimir
- Venue
- Journal of Infection and Chemotherapy
- Publisher
- Elsevier BV
- Published
- 2000
- Volume
- 6
- Issue
- 4
- Pages
- 216-221
- ISSN
- 1341-321X (ISSN-L)
- OpenAlex
- W2026315364
- Cited by
- 39
- References
- 11
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 2 · 2020: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2014: 1 · 2013: 2
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Journal of Infection and Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal susceptibility, bloodstream candidiasis, fungemia, fluconazole resistance, Candida albicans, non-albicans Candida, Candida glabrata, Candida krusei, Candida parapsilosis, Candida guilliermondii, amphotericin B, 5-fluorocytosine, itraconazole, ketoconazole, miconazole, nystatin, antifungal resistance, cancer patients, critically ill patients, surgical patients, neonatal patients, treatment outcomes
- MeSH terms
- Adult, Antifungal Agents, Candida, Candida albicans, Child, Humans, Infant, Newborn, Microbial Sensitivity Tests, Neoplasms, Yeasts, Fluconazole, Survival Analysis, Fungemia, Slovakia, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.